HIV-1 Antiretroviral Resistance: Scientific Principles and Clinical Applications
Open accessThe DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Abstract
The efficacy of an antiretroviral (ARV) treatment regimen depends on the activity of the regimen’s individual ARV drugs and the number of HIV-1 mutations required for the development of resistance to each ARV — the genetic barrier to resistance. ARV resistance impairs the response to therapy in patients with transmitted resistance, unsuccessful initial ARV therapy and multiple virological failures. Genotypic resistance testing is used to identify transmitted drug resistance, provide insight into the reasons for virological failure in treated patients, and help guide second-line and salvage therapies. In patients with transmitted drug resistance, the virological response to a regimen selected on the basis of standard genotypic testing approaches the responses observed in patients with wild-type viruses. However, because such patients are at a higher risk of harbouring minority drug-resistant variants, initial ARV therapy in this population should contain a boosted protease inhibitor (PI) — the drug class with the highest genetic barrier to resistance.In patients receiving an initial ARV regimen with a high genetic barrier to resistance, the most common reasons for virological failure are nonadherence and, potentially, pharmacokinetic factors or minority transmitted drug-resistant variants. Among patients in whom first-line ARVs have failed, the patterns of drug-resistance mutations and cross-resistance are often predictable. However, the extent of drug resistance correlates with the duration of uncontrolled virological replication. Second-line therapy should include the continued use of a dual nucleoside/nucleotide reverse transcriptase inhibitor (NRTI)-containing backbone, together with a change in the non-NRTI component, most often to an ARV belonging to a new drug class.The number of available fully active ARVs is often diminished with each successive treatment failure. Therefore, a salvage regimen is likely to be more complicated in that it may require multiple ARVs with partial residual activity and compromised genetic barriers of resistance to attain complete virological suppression. A thorough examination of the patient’s ARV history and prior resistance tests should be performed because genotypic and/or phenotypic susceptibility testing is often not sufficient to identify drug-resistant variants that emerged during past therapies and may still pose a threat to a new regimen. Phenotypic testing is also often helpful in this subset of patients. ARVs used for salvage therapy can be placed into the following hierarchy: (i) ARVs belonging to a previously unused drug class; (ii) ARVs belonging to a previously used drug class that maintain significant residual antiviral activity; (iii) NRTI combinations, as these often appear to retain in vivo virological activity, even in the presence of reduced in vitro NRTI susceptibility; and rarely (iv) ARVs associated with previous virological failure and drug resistance that appear to have possibly regained their activity as a result of viral reversion to wild type. Understanding the basic principles of HIV drug resistance is helpful in guiding individual clinical decisions and the development of ARV treatment guidelines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time
Perelson, A. S., Neumann, A. U., Markowitz, M., Leonard, J. M., & Ho, D. D. (1996) · Science · doi:10.1126/science.271.5255.1582 · Cited by 3,531
Thompson, M. A., Aberg, J. A., Hoy, J. F., Telenti, A., Benson, C., Cahn, P., Eron, J. J., Günthard, H. F., Hammer, S. M., Reiss, P., et al. (2012) · JAMA · doi:10.1001/jama.2012.7961 · Cited by 2,469
HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy
Coffin, J. M. (1995) · Science · doi:10.1126/science.7824947 · Cited by 1,981
Keele, B. F., Giorgi, E. E., Salazar-Gonzalez, J. F., Decker, J. M., Pham, K. T., Salazar, M. G., Sun, C., Grayson, T., Wang, S., Li, H., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802203105 · Cited by 1,912
Gallant, J. E. (2004) · JAMA · doi:10.1001/jama.292.2.191 · Cited by 1,341 · cited 2×
“[134] Several lines of evidence suggest that patients infected with subtype C viruses who are treated with stavudine/lamivudine/efavirenz or stavudine/ lamivudine/nevirapine may be more prone than patients infected with subtype B viruses to develop the NRTI-resistance mutation, K65R.”
BackgroundHammer, S. M., Eron, J. J., Reiss, P., Schooley, R. T., Thompson, M. A., Walmsley, S., Cahn, P., Fischl, M. A., Gatell, J. M., Hirsch, M. S., et al. (2008) · JAMA · doi:10.1001/jama.300.5.555 · Cited by 1,026
Hirsch, M. S., Brun-Vézinet, F., D'Aquila, R. T., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Loveday, C., Mellors, J. W., Clotet, B., Conway, B., et al. (2000) · JAMA · doi:10.1001/jama.283.18.2417 · Cited by 766
Maraviroc for Previously Treated Patients with R5 HIV-1 Infection
Gulick, R. M., Lalezari, J., Goodrich, J., Clumeck, N., DeJesus, E., Horban, A., Nadler, J., Clotet, B., Karlsson, A., Wohlfeiler, M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0803152 · Cited by 752
Thompson, M. A., Aberg, J. A., Cahn, P., Montaner, J. S. G., Rizzardini, G., Telenti, A., Gatell, J. M., Günthard, H. F., Hammer, S. M., Hirsch, M. S., et al. (2010) · JAMA · doi:10.1001/jama.2010.1004 · Cited by 722
Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
Steigbigel, R. T., Cooper, D. A., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Gatell, J. M., Rockstroh, J. K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708975 · Cited by 691
Integrase inhibitors to treat HIV/Aids
Pommier, Y., Johnson, A. A., & Marchand, C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1660 · Cited by 688
Goonetilleke, N., Liu, M. K. P., Salazar-Gonzalez, J. F., Ferrari, G., Giorgi, E., Ganusov, V. V., Keele, B. F., Learn, G. H., Turnbull, E. L., Salazar, M. G., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090365 · Cited by 641
Lennox, J. L., DeJesus, E., Lazzarin, A., Pollard, R. B., Madruga, J. V. R., Berger, D. S., Zhao, J., Xu, X., Williams-Diaz, A., Rodgers, A. J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60918-1 · Cited by 625
Hirsch, M. S., Günthard, H. F., Schapiro, J. M., Brun‐Vézinet, F., Clotet, B., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Mellors, J. W., Pillay, D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/589297 · Cited by 573
Eron, J. J., Benoit, S. L., Jemsek, J., MacArthur, R. D., Santana, J., Quinn, J. B., Kuritzkes, D. R., Fallon, M. A., & Rubin, M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512213332502 · Cited by 531
Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection
Cooper, D. A., Steigbigel, R. T., Gatell, J. M., Rockstroh, J. K., Katlama, C., Yeni, P., Lazzarin, A., Clotet, B., Kumar, P. N., Eron, J. E., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708978 · Cited by 509
Palmer, S., Kearney, M., Maldarelli, F., Halvas, E. K., Bixby, C. J., Bazmi, H., Rock, D., Falloon, J., Davey, R. T., Dewar, R. L., et al. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.1.406-413.2005 · Cited by 506
Fätkenheuer, G., Pozniak, A. L., Johnson, M. A., Plettenberg, A., Staszewski, S., Hoepelman, A. I. M., Saag, M. S., Goebel, F. D., Rockstroh, J. K., Dezube, B. J., et al. (2005) · Nature Medicine · doi:10.1038/nm1319 · Cited by 495
Molina, J.-M., Andrade-Villanueva, J., Echevarria, J., Chetchotisakd, P., Corral, J., David, N., Moyle, G., Mancini, M., Percival, L., Yang, R., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61081-8 · Cited by 486
Hu, W. S., & Temin, H. M. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.4.1556 · Cited by 476
Dynamics of HIV-1 recombination in its natural target cells
Levy, D. N., Aldrovandi, G. M., Kutsch, O., & Shaw, G. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306764101 · Cited by 441
Wang, C., Mitsuya, Y., Gharizadeh, B., Ronaghi, M., & Shafer, R. W. (2007) · Genome Research · doi:10.1101/gr.6468307 · Cited by 408
Self-citationSimen, B. B., Simons, J. F., Hullsiek, K. H., Novak, R. M., MacArthur, R. D., Baxter, J. D., Huang, C., Lubeski, C., Turenchalk, G. S., Braverman, M. S., et al. (2009) · Journal of Infectious Diseases · doi:10.1086/596736 · Cited by 392
Cohen, C. J., Andrade-Villanueva, J., Clotet, B., Fourie, J., Johnson, M. A., Ruxrungtham, K., Wu, H., Zorrilla, C., Crauwels, H., Rimsky, L. T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60983-5 · Cited by 374
Johnson, J. A., Li, J.-F., Wei, X., Lipscomb, J., Irlbeck, D., Craig, C., Smith, A., Bennett, D. E., Monsour, M., Sandstrom, P., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050158 · Cited by 371
Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection
Fätkenheuer, G., Nelson, M., Lazzarin, A., Konourina, I., Hoepelman, A. I. M., Lampiris, H., Hirschel, B., Tebas, P., Raffi, F., Trottier, B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0803154 · Cited by 364
Whitcomb, J. M., Huang, W., Fransen, S., Limoli, K., Toma, J., Wrin, T., Chappey, C., Kiss, L. D. B., Paxinos, E. E., & Petropoulos, C. J. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00853-06 · Cited by 356
Westby, M., Smith-Burchnell, C., Mori, J., Lewis, M., Mosley, M., Stockdale, M., Dorr, P., Ciaramella, G., & Perros, M. (2007) · Journal of Virology · doi:10.1128/jvi.02006-06 · Cited by 350
Westby, M., Lewis, M., Whitcomb, J., Youle, M., Pozniak, A. L., James, I. T., Jenkins, T. M., Perros, M., & van der Ryst, E. (2006) · Journal of Virology · doi:10.1128/jvi.80.10.4909-4920.2006 · Cited by 337
Madruga, J. V., Berger, D., McMurchie, M., Suter, F., Banhegyi, D., Ruxrungtham, K., Norris, D., Lefebvre, E., de Béthune, M.-P., Tomaka, F., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61049-6 · Cited by 336
Espeseth, A. S., Felock, P., Wolfe, A., Witmer, M., Grobler, J., Anthony, N., Egbertson, M., Melamed, J. Y., Young, S., Hamill, T., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.200139397 · Cited by 317 · cited 3×
“[86] Although integrase catalyzes both the 30-processing and strand-transfer reactions, only those compounds that specifically inhibit strand transfer have been effective INIs because INIs bind only to those enzymes that are already bound to viral DNA.”
BackgroundInfluentialAbacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy
Sax, P. E., Tierney, C., Collier, A. C., Fischl, M. A., Mollan, K., Peeples, L., Godfrey, C., Jahed, N. C., Myers, L., Katzenstein, D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906768 · Cited by 313
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use
Trkola, A., Kuhmann, S. E., Strizki, J. M., Maxwell, E., Ketas, T., Morgan, T., Pugach, P., Xu, S., Wojcik, L., Tagat, J., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012519099 · Cited by 303
van Lunzen, J., Maggiolo, F., Arribas, J. R., Rakhmanova, A., Yeni, P., Young, B., Rockstroh, J. K., Almond, S., Song, I., Brothers, C., et al. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70290-0 · Cited by 301
Hosseinipour, M. C., van Oosterhout, J. J., Weigel, R., Phiri, S., Kamwendo, D., Parkin, N., Fiscus, S. A., Nelson, J. A., Eron, J. J., & Kumwenda, J. (2009) · AIDS · doi:10.1097/qad.0b013e32832ac34e · Cited by 288
Hamers, R. L., Wallis, C. L., Kityo, C., Siwale, M., Mandaliya, K., Conradie, F., Botes, M. E., Wellington, M., Osibogun, A., Sigaloff, K. C. E., et al. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70149-9 · Cited by 287
DeJesus, E., Berger, D., Markowitz, M., Cohen, C., Hawkins, T., Ruane, P., Elion, R., Farthing, C., Zhong, L., Cheng, A. K., et al. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000233308.82860.2f · Cited by 270 · cited 1×
“Nucleoside/nucleotide reverse transcriptase inhibitors are depicted in black, non-nucleoside reverse transcriptase inhibitors are green, protease inhibitors are red, integrase inhibitors are blue, maraviroc is purple and enfuvirtide is orange.([13-21]) Refer to table I for a full list of drug name abbreviations and de…”
BackgroundBrumme, Z. L., Goodrich, J., Mayer, H. B., Brumme, C. J., Henrick, B. M., Wynhoven, B., Asselin, J. J., Cheung, P. K., Hogg, R. S., Montaner, J. S. G., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/431519 · Cited by 270
Nature, Position, and Frequency of Mutations Made in a Single Cycle of HIV-1 Replication
Abram, M. E., Ferris, A. L., Shao, W., Alvord, W. G., & Hughes, S. H. (2010) · Journal of Virology · doi:10.1128/jvi.00915-10 · Cited by 267
Yazdanpanah, Y., Fagard, C., Descamps, D., Taburet, A. M., Colin, C., Roquebert, B., Katlama, C., Pialoux, G., Jacomet, C., Piketty, C., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/630210 · Cited by 239
Murphy, R. L., Brun, S., Hicks, C., Eron, J. J., Gulick, R., King, M., White, A. C., Benson, C., Thompson, M., Kessler, H. A., et al. (2001) · AIDS · doi:10.1097/00002030-200101050-00002 · Cited by 238
HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications
Blanco, J.-L., Varghese, V., Rhee, S.-Y., Gatell, J. M., & Shafer, R. W. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir025 · Cited by 218
Self-citationWinters, M. A., Coolley, K. L., Girard, Y. A., Levee, D. J., Hamdan, H., Shafer, R. W., Katzenstein, D. A., & Merigan, T. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci4948 · Cited by 216
Self-citationHIV-1 Protease Mutations and Protease Inhibitor Cross-Resistance
Rhee, S.-Y., Taylor, J., Fessel, W. J., Kaufman, D., Towner, W., Troia, P., Ruane, P., Hellinger, J., Shirvani, V., Zolopa, A., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00574-10 · Cited by 216
Self-citationWheeler, W. H., Ziebell, R. A., Zabina, H., Pieniazek, D., Prejean, J., Bodnar, U. R., Mahle, K. C., Heneine, W., Johnson, J. A., & Hall, H. I. (2010) · AIDS · doi:10.1097/qad.0b013e3283388742 · Cited by 213
Kilby, J. M., Lalezari, J. P., Eron, J. J., Carlson, M., Cohen, C., Arduino, R. C., Goodgame, J. C., Gallant, J. E., Volberding, P., Murphy, R. L., et al. (2002) · AIDS Research and Human Retroviruses · doi:10.1089/088922202760072294 · Cited by 198
Gupta, R., Hill, A., Sawyer, A. W., & Pillay, D. (2008) · Clinical Infectious Diseases · doi:10.1086/590943 · Cited by 187
Arribas, J. R., Horban, A., Gerstoft, J., Fätkenheuer, G., Nelson, M., Clumeck, N., Pulido, F., Hill, A., van Delft, Y., Stark, T., et al. (2010) · AIDS · doi:10.1097/qad.0b013e3283348944 · Cited by 186
Vingerhoets, J., Tambuyzer, L., Azijn, H., Hoogstoel, A., Nijs, S., Peeters, M., de Béthune, M.-P., De Smedt, G., Woodfall, B., & Picchio, G. (2010) · AIDS · doi:10.1097/qad.0b013e32833677ac · Cited by 185
Wilkin, T. J., Su, Z., Kuritzkes, D. R., Hughes, M., Flexner, C., Gross, R., Coakley, E., Greaves, W., Godfrey, C., Skolnik, P. R., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/511035 · Cited by 183
Wheeler, Ziebell, Zabina, & Pieniazek (2010) · AIDS · Cited by 182
Strand transfer inhibitors of HIV-1 integrase: Bringing IN a new era of antiretroviral therapy
McColl, D. J., & Chen, X. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.11.004 · Cited by 173
Rimsky, L., Vingerhoets, J., Van Eygen, V., Eron, J., Clotet, B., Hoogstoel, A., Boven, K., & Picchio, G. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31823df4da · Cited by 173
Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors
Sluis-Cremer, N., & Tachedjian, G. (2008) · Virus Research · doi:10.1016/j.virusres.2008.01.002 · Cited by 172
Fransen, S., Gupta, S., Danovich, R., Hazuda, D., Miller, M., Witmer, M., Petropoulos, C. J., & Huang, W. (2009) · Journal of Virology · doi:10.1128/jvi.01168-09 · Cited by 172
Molina, J.-M., LaMarca, A., Andrade-Villanueva, J., Clotet, B., Clumeck, N., Liu, Y.-P., Zhong, L., Margot, N., Cheng, A. K., & Chuck, S. L. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70249-3 · Cited by 171
Katlama, C., Valantin, M. A., Algarte-Genin, M., Duvivier, C., Lambert-Niclot, S., Girard, P. M., Molina, J. M., Hoen, B., Pakianather, S., Peytavin, G., et al. (2010) · AIDS · doi:10.1097/qad.0b013e32833dec20 · Cited by 166
Larder, B. A. (1994) · Journal of General Virology · doi:10.1099/0022-1317-75-5-951 · Cited by 166
Swenson, L. C., Mo, T., Dong, W. W. Y., Zhong, X., Woods, C. K., Jensen, M. A., Thielen, A., Chapman, D., Lewis, M., James, I., et al. (2010) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiq030 · Cited by 156
Sista, P. R., Melby, T., Davison, D. K., Jin, L., Mosier, S. M., Mink, M., Nelson, E. L., DeMasi, R. A., Cammack, N., Salgo, M., et al. (2004) · AIDS · doi:10.1097/00002030-200409030-00007 · Cited by 154
The HIVdb System for HIV-1 Genotypic Resistance Interpretation
Tang, M. W., Liu, T. F., & Shafer, R. W. (2012) · Intervirology · doi:10.1159/000331998 · Cited by 153
Self-citationNelson, M., Arastéh, K., Clotet, B., Cooper, D. A., Henry, K., Katlama, C., Lalezari, J. P., Lazzarin, A., Montaner, J. S. G., O'Hearn, M., et al. (2005) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000185314.56556.c3 · Cited by 153
Deeks, S. G., Hoh, R., Neilands, T. B., Liegler, T. J., Aweeka, F. T., Petropoulos, C. J., Grant, R. M., & Martin, J. N. (2005) · The Journal of Infectious Diseases · doi:10.1086/496892 · Cited by 151
Molecular Basis for Drug Resistance in HIV-1 Protease
Ali, A., Bandaranayake, R. M., Cai, Y., King, N. M., Kolli, M., Mittal, S., Foulkes-Murzycki, J. E., Nalam, M. N. L., Nalivaika, E. A., Özen, A., et al. (2010) · Viruses · doi:10.3390/v2112509 · Cited by 146
Hunt, P. W., Harrigan, P. R., Huang, W., Bates, M. P., Williamson, D. W., McCune, J. M., Price, R. W., Spudich, S., Lampiris, H. W., Hoh, R., et al. (2006) · The Journal of Infectious Diseases · doi:10.1086/507312 · Cited by 146
Lü, J., Sista, P. R., Giguel, F. F., Greenberg, M., & Kuritzkes, D. R. (2004) · Journal of Virology · doi:10.1128/jvi.78.9.4628-4637.2004 · Cited by 144
European recommendations for the clinical use of HIV drug resistance testing: 2011 update.
Vandamme, A., Camacho, R. J., Ceccherini‐Silberstein, F., de Luca, A., Palmisano, L., Paraskevis, D. N., Paredes, R., Poljak, M., Schmit, J., Soriano, V., et al. (2011) · PubMed · Cited by 142
National Institute of Allergy and Infectious Diseases (NIAID): An Overview
Western, K. A. (2008) · National Institute of Allergy and Infectious Diseases, NIH · doi:10.1007/978-1-59745-569-5_1 · Cited by 139
Delelis, O., Malet, I., Na, L., Tchertanov, L., Calvez, V., Marcelin, A.-G., Subra, F., Deprez, E., & Mouscadet, J.-F. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn1050 · Cited by 139
Marcelin, A., Delaugerre, C., Wirden, M., Viegas, P., Simon, A., Katlama, C., & Cálvez, V. (2003) · Journal of Medical Virology · doi:10.1002/jmv.10550 · Cited by 136
Ren, J., & STAMMERS, D. K. (2008) · Virus Research · doi:10.1016/j.virusres.2007.12.018 · Cited by 135
Short-term antiviral activity of TMC278 – a novel NNRTI – in treatment-naive HIV-1-infected subjects
Goebel, F. D., Yakovlev, A., Pozniak, A., Vinogradova, E., Boogaerts, G., Hoetelmans, R. M. W., de Béthune, M., Peeters, M., & Woodfall, B. (2006) · AIDS · doi:10.1097/01.aids.0000242818.65215.bd · Cited by 128
Antiviral Activity of Lamivudine in Salvage Therapy for Multidrug‐Resistant HIV‐1 Infection
Campbell, T., Shulman, N. S., Johnson, S. C., Zolopa, A. R., Young, R. K., Bushman, L. R., Fletcher, C. V., Lanier, E. R., Merigan, T. C., & Kuritzkes, D. R. (2005) · Clinical Infectious Diseases · doi:10.1086/430709 · Cited by 124
Rapid Emergence of Enfuvirtide Resistance in HIV-1-Infected Patients: Results of a Clonal Analysis
Lü, J., Deeks, S. G., Hoh, R., Beatty, G. W., Kuritzkes, B. A., Martin, J. N., & Kuritzkes, D. R. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000234083.34161.55 · Cited by 114
Melby, T., DeSpirito, M., DeMasi, R., Heilek‐Snyder, G., Greenberg, M. L., & Graham, N. (2006) · The Journal of Infectious Diseases · doi:10.1086/504693 · Cited by 112
A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors
Moore, J. P., & Kuritzkes, D. R. (2009) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e3283223d46 · Cited by 102
Canducci, F., Ceresola, E. R., Boeri, E., Spagnuolo, V., Cossarini, F., Castagna, A., Lazzarin, A., & Clementi, M. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir636 · Cited by 102
Xu, H., Asahchop, E. L., Oliveira, M., Quashie, P. K., Quan, Y., BRENNER, B. G., & Wainberg, M. A. (2011) · Journal of Virology · doi:10.1128/jvi.05584-11 · Cited by 101
Oette, M., Kaiser, R., Däumer, M., Petch, R., Fätkenheuer, G., Carls, H., Rockstroh, J. K., Schmalöer, D., Stechel, J., Feldt, T., et al. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000214805.52723.c1 · Cited by 100
Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase
Singh, K., Marchand, B., Kirby, K. A., Michailidis, E., & Sarafianos, S. G. (2010) · Viruses · doi:10.3390/v2020606 · Cited by 99
Swenson, L. C., Mo, T., Dong, W. W. Y., Zhong, X., Woods, C. K., Thielen, A., Jensen, M. A., Knapp, D. J. H. F., Chapman, D. S., Portsmouth, S., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir493 · Cited by 97
Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1
Whitcomb, J. M., Huang, W., Limoli, K. L., Paxinos, E. E., Wrin, T., Skowron, G., Deeks, S. G., Bates, M. P., Hellmann, N. S., & Petropoulos, C. J. (2002) · AIDS · doi:10.1097/00002030-200210180-00002 · Cited by 96
Goodman, D. D., Zhou, Y., Margot, N., McColl, D. J., Zhong, L., Borroto–Esoda, K., Miller, M. D., & Svarovskaia, E. S. (2010) · AIDS · doi:10.1097/qad.0b013e3283427dcb · Cited by 96
Varghese, V., Shahriar, R., Rhee, S., Liu, T. F., Simen, B. B., Egholm, M., Hanczaruk, B., Blake, L. A., Gharizadeh, B., Babrzadeh, F., et al. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181bca669 · Cited by 96
Self-citationPoveda, E., Briz, V., Quiñones‐Mateu, M. E., & Soriano, V. (2006) · AIDS · doi:10.1097/01.aids.0000233569.74769.69 · Cited by 94
Vaerenbergh, K. V., Laethem, K. V., Albert, J., Boucher, C. A., Clotet, B., Floridia, M., Gerstoft, J., Hejdeman, B., Nielsen, C. H., Pannecouque, C. C., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.8.2109-2117.2000 · Cited by 94
Kulkarni, R., Babaoglu, K., Lansdon, E. B., Rimsky, L. T., Eygen, V. V., Picchio, G., Svarovskaia, E. S., Miller, M. D., & White, K. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31823aca74 · Cited by 87
Parikh, U. M., Zelina, S., Sluis‐Cremer, N., & Mellors, J. W. (2007) · AIDS · doi:10.1097/qad.0b013e3281ac229b · Cited by 86
Louie, M. J., Hogan, C., Hurley, A., Simon, V. R., Chung, C., Padte, N. N., Lamy, P. D., Flaherty, J. F., Coakley, D. F., Mascio, M. D., et al. (2003) · AIDS · doi:10.1097/00002030-200305230-00006 · Cited by 83
Swenson, L. C., Moores, A., Low, A., Thielen, A., Dong, W. W. Y., Woods, C. K., Jensen, M. A., Wynhoven, B., Chan, D., Glascock, C. B., et al. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181d0558f · Cited by 81
Menzo, S., Castagna, A., Monachetti, A., Hasson, H., Danise, A., Carini, E., Bagnarelli, P., Lazzarin, A., & Clementi, M. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.9.3253-3259.2004 · Cited by 80
Tang, M. W., Kanki, P., & Shafer, R. W. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir1034 · Cited by 71
Self-citationCozzi‐Lepri, A., Ruiz, L., Loveday, C., Phillips, A. N., Clotet, B., Reiss, P., Ledergerber, B., Holkmann, C., Staszewski, S., Lundgren, J. D., et al. (2005) · Antiviral Therapy · doi:10.1177/135965350501000705 · Cited by 69
The impact of the M184V substitution in HIV‐1 reverse transcriptase on treatment response
Miller, V., Stark, T., Loeliger, A., & Lange, J. M. A. (2002) · HIV Medicine · doi:10.1046/j.1468-1293.2002.00101.x · Cited by 67
HIV mutagenesis and the evolution of antiretroviral drug resistance
Mansky, L. M. (2002) · Drug Resistance Updates · doi:10.1016/s1368-7646(02)00118-8 · Cited by 67
Sugiura, W., Matsuda, Z., Yokomaku, Y., Hertogs, K., Larder, B. A., Oishi, T., Okano, A., Shiino, T., Tatsumi, M., Matsuda, M., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.3.708-715.2002 · Cited by 67
Invernizzi, C. F., Coutsinos, D., Oliveira, M., Moisi, D. D., BRENNER, B. G., & Wainberg, M. A. (2009) · The Journal of Infectious Diseases · doi:10.1086/605894 · Cited by 65
Melikian, G., Rhee, S., Taylor, J., Fessel, W. J., Kaufman, D., Towner, W. J., Troia-Cancio, P. V., Zolopa, A. R., Robbins, G. K., Kagan, R. M., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05487-11 · Cited by 63
Self-citationEstimating HIV‐1 Drug Resistance in Antiretroviral‐Treated Individuals in the United Kingdom
UK Collaborative Group on HIV Drug Resistance (2005) · The Journal of Infectious Diseases · doi:10.1086/432763 · Cited by 62
Tambuyzer, L., Vingerhoets, J., Azijn, H., Daems, B., Nijs, S., de Béthune, M., & Picchio, G. (2010) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2009.0302 · Cited by 60
Hu, Z., & Kuritzkes, D. R. (2011) · Journal of Virology · doi:10.1128/jvi.05578-11 · Cited by 59
Calazans, A., Brindeiro, R., Brindeiro, P. A., Verli, H., Arruda, M. B., Gonzalez, L. M. F., Guimarães, J. A., Diaz, R. S., Antunes, O. A. C., & Tanuri, A. (2005) · The Journal of Infectious Diseases · doi:10.1086/430002 · Cited by 58
Scherrer, A., Ledergerber, B., von Wyl, V., Böni, J., Yerly, S., Klimkait, T., Bürgisser, P., Rauch, A., Hirschel, B. J., Cavassini, M. L., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir669 · Cited by 58
Naeger, L. K., & Struble, K. A. (2006) · AIDS · doi:10.1097/01.aids.0000218548.77457.76 · Cited by 46
Cabrera, C., Marfil, S., García, E., Martínez‐Picado, J., Bonjoch, A., Bofill, M., Moreno, S., Ribera, E., Domingo, P., Clotet, B., et al. (2006) · AIDS · doi:10.1097/qad.0b013e3280102377 · Cited by 43
Borroto–Esoda, K., Waters, J. M., Bae, A. S., Harris, J. L., Hinkle, J. E., Quinn, J., & Rousseau, F. (2007) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2006.0310 · Cited by 41
Marcelin, A., Reynes, J., Yerly, S., Ktorza, N., Segondy, M., Piot, J.-C., Delfraissy, J., Kaiser, L., Perrin, L. H., Katlama, C., et al. (2004) · AIDS · doi:10.1097/00002030-200406180-00015 · Cited by 40
When and how to use maraviroc in HIV-infected patients
Soriano, V., Perno, C. F., Kaiser, R., Cálvez, V., Gatell, J. M., Perri, G. D., Pillay, D., Rockstroh, J., & Geretti, A. M. (2009) · AIDS · doi:10.1097/qad.0b013e328332d32d · Cited by 39
TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen
Sankatsing, S. U., Weverling, G. J., Peeters, M., Klooster, G. A. E. V. '., Груздев, Б. М., Rakhmanova, A. G., Danner, S. A., Jurriaans, S., Prins, J. M., & Lange, J. M. A. (2003) · AIDS · doi:10.1097/00002030-200312050-00009 · Cited by 38
Ferns, R. B., Kirk, S., Bennett, J., Williams, I. G., Edwards, S., & Pillay, D. (2009) · AIDS · doi:10.1097/qad.0b013e32832ec4ae · Cited by 32
Barber, T., Harrison, L., Asboe, D., Williams, I. G., Kirk, S., Gilson, R. J. C., Bansi‐Matharu, L., Pillay, D., & Dunn, D. T. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr569 · Cited by 27
Morand‐Joubert, L., Charpentier, C., Poizat, G., Chêne, G., Dam, E., Raguin, G., Taburet, A., Girard, P., Hance, A. J., & Clavel, F. (2006) · Antiviral Therapy · doi:10.1177/135965350601100211 · Cited by 24
Cossarini, F., Galli, L., Sagnelli, C., Gianotti, N., Hasson, H., Clementi, M., Soria, A., Salpietro, S., Lazzarin, A., & Castagna, A. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181a56f46 · Cited by 7
Cited by
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases
Jordheim, L. P., Durantel, D., Zoulim, F., & Dumontet, C. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4010 · Cited by 1,211
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
Sarrazin, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.09.011 · Cited by 423
Programmable Inhibition and Detection of RNA Viruses Using Cas13
Freije, C. A., Myhrvold, C., Boehm, C. K., Lin, A. E., Welch, N. L., Carter, A., Metsky, H. C., Luo, C. Y., Abudayyeh, O. O., Gootenberg, J. S., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.09.013 · Cited by 393
Usach, I., Melis, V., & Peris, J. (2013) · Journal of the International AIDS Society · doi:10.7448/ias.16.1.18567 · Cited by 373
HIV-1 drug resistance and resistance testing
Clutter, D. S., Jordan, M. R., Bertagnolio, S., & Shafer, R. W. (2016) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2016.08.031 · Cited by 333
Self-citation
Metadata
- Authors
- Tang, M. W., & Shafer, R. W.
- Venue
- Drugs
- Published
- 2012-06
- Volume
- 72
- Issue
- 9
- Pages
- e1-e25
- ISSN
- 0012-6667 (ISSN-L)
- OpenAlex
- W2069388608
- Cited by
- 326
- References
- 114
- FWCI
- 19.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.